Description: This is the Array Biopharma, Inc Securities Litigation
inc (1198) inc litigation (13) array biopharma (3)
The information contained on this website is only a summary of the information presented in more detail in the Notice of Pendency and Proposed Settlement of Class Action. Because this website is just a summary, you should review the Notice for additional details.
The Notice relates to a proposed Settlement of claims in a pending securities class action brought by Plaintiffs alleging that Defendants intentionally or recklessly made false and materially misleading statements and omissions concerning the results of Array BioPharma, Inc.’s ("Array") Phase 3 clinical trial (referred to as the NEMO trial) for binimetinib. Plaintiffs further allege that these purportedly false and materially misleading statements and omissions induced Plaintiffs and other similarly situate
Defendants have denied and continue to deny each and all of the claims and allegations of wrongdoing made by Plaintiffs in the Action and maintain furthermore that they have meritorious defenses. Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Action. Defendants also have denied and continue to deny, among other allegations, the allegat